 | • レポートコード：B-MOR-08343 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、メラノーマの診断および治療の世界市場について調べ、メラノーマの診断および治療の世界規模、市場動向、市場環境、がんの種類別（表在拡大型黒色腫、結節型黒色腫、悪性黒子黒色腫、末端黒子型黒色腫、無色素性黒色腫、その他）分析、診断別（皮膚鏡検査、センチネルリンパ節生検、血液検査、X線、超音波、CTスキャン）分析、治療別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・メラノーマの診断および治療の世界市場インサイト ・メラノーマの診断および治療の世界市場環境 ・メラノーマの診断および治療の世界市場動向 ・メラノーマの診断および治療の世界市場規模 ・メラノーマの診断および治療の世界市場規模：がんの種類別（表在拡大型黒色腫、結節型黒色腫、悪性黒子黒色腫、末端黒子型黒色腫、無色素性黒色腫、その他） ・メラノーマの診断および治療の世界市場規模：診断別（皮膚鏡検査、センチネルリンパ節生検、血液検査、X線、超音波、CTスキャン） ・メラノーマの診断および治療の世界市場規模：治療別 ・メラノーマの診断および治療の世界市場：地域別市場規模・分析 ・メラノーマの診断および治療の北米市場規模・予測 ・メラノーマの診断および治療のアメリカ市場規模・予測 ・メラノーマの診断および治療のヨーロッパ市場規模・予測 ・メラノーマの診断および治療のアジア市場規模・予測 ・メラノーマの診断および治療の日本市場規模・予測 ・メラノーマの診断および治療の中国市場規模・予測 ・メラノーマの診断および治療のインド市場規模・予測 ・メラノーマの診断および治療の韓国市場規模・予測 ・関連企業情報・競争状況 |
The melanoma diagnostics and therapeutics market are expected to register a CAGR of about 15%, during the forecast period, 2018 to 2023. Melanoma is one of the serious types of skin cancer that develops from pigment-containing cells called melanocytes. The market for melanoma diagnostics and therapeutics is increasing at a significant rate due to an increase in the prevalence of melanoma and improvement in healthcare facilities. The melanoma diagnostics and therapeutics market are going to witness growth in the forecasted future.
Increasing Incidences of Melanoma Cases
Melanoma is one of the major causes of morbidity and mortality in the US. It is one of the most common types of cancer in men and women. Among young adults, melanoma is the second most common invasive cancer. The lifetime risk of melanoma is 1.5 times higher in males than in females. The rising number of cases of melanoma will eventually lead to the high CAGR for the melanoma diagnostics and therapeutics market. Along with this the effective immunotherapies, label extension of current therapies into the new settings and government initiatives will play a major role in driving the market for melanoma diagnostics and therapeutics.
High Costs Associated with the Therapy
Managing the after-effects resulting from melanoma treatment can incur significant costs, even accounting for variation in country-level or individual differences in treatment approach. Payer-perspective costs of total resources administered or recommended by a medical oncologist or dermatologist (i.e., not including resources required for continuing care by another specialist), ranged from the cost of an excess physician visit to high hospitalization costs. This is a conservative estimate of the resources used to treat toxicities related to metastatic melanoma treatments, if other specialists are consulted to manage specific events, for instance, additional resources may be required. This acts as a deterrent for patients with melanoma from getting the best treatments available. Along with that lack of awareness about melanoma in some of the developing and underdeveloped nations and stringent regulatory issues will lead to the slowdown in the growth of the melanoma diagnostics and therapeutics market.
North America to Witness Considerable Growth in the Forecast Period
North America currently has the most advanced diagnostics and therapeutics available and the level of awareness about melanoma and the diagnostics and therapeutics involved will lead the US to witness the maximum CAGR. APAC and Europe will also witness substantial growth owing huge population base and rising incidence of melanoma in these regions.
Key Developments in the Market
• December 2017 – FDA granted regular approval to the anti-PD1 monoclonal antibody, nivolumab (OPDIVO, Bristol-Myers Squibb Company) for the adjuvant treatment of patients with melanoma with the involvement of lymph nodes or in patients with metastatic disease who have undergone complete resection. Nivolumab was previously approved for the treatment of patients with unresectable or metastatic melanoma
Major players- ABBOTT DIAGNOSTICS, AGILENT TECHNOLOGIES, ASTRAZENECA, BRISTOL-MYERS SQUIBB, ELI LILLY, GLAXOSMITHKLINE, MERCK, NOVARTIS, PFIZER, QIAGEN N.V. COMPANY, ROCHE, AND SANOFI, amongst others.
Reasons to Purchase this Report
• Current and future melanoma diagnostics and therapeutics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidences of Melanoma Cases
6.1.2 Effective Immunotherapies
6.1.3 Label Extension of Current Therapies into the New Settings
6.1.4 Government Initiatives
6.2 Market Restraints
6.2.1 Lack of Awareness in about Melanoma
6.2.2 High Cost Associated with the Therapy
6.2.3 Stringent Regulatory Issues
7. Market Segmentation
7.1 By Cancer Type
7.1.1 Superficial Spreading Melanoma
7.1.2 Nodular Melanoma
7.1.3 Lentigno Maligna Melanoma
7.1.4 Acral Lentiginous Melanoma
7.1.5 Amelanotic Melanoma
7.1.6 Others
7.2 By Diagnosis
7.2.1 Dermatoscopy
7.2.2 Sentinel Lymph Node Biopsy
7.2.3 Blood Tests
7.2.4 X-Rays
7.2.5 Ultrasound
7.2.6 Ct Scan
7.3 By Treatment
7.3.1 Chemotherapy
7.3.2 Biological Therapy
7.3.3 Radiotherapy
7.3.4 Targeted Therapy
7.3.5 Immune Therapy
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest Of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott Diagnostics
9.2 Agilent Technologies
9.3 AstraZeneca
9.4 Bristol-Myers Squibb
9.5 Eli Lilly
9.6 GlaxoSmithKline
9.7 Merck
9.8 Novartis
9.9 Pfizer
9.10 Qiagen N.V. Company
9.11 Roche
9.12 Sanofi
9.13 List Not Exhaustive
10. Future of the Market